

March 8, 2013

Notification on the results of the phase III clinical study in Japan for the addition of efficacy for “chronic pain” using the transdermal, long-acting cancer pain relief patch FENTOS® TAPE (development code: HFT-290)

Hisamitsu Pharmaceutical Co., Inc., (head office: Tosu-shi, Saga, Japan; president & CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu Pharmaceutical) hereby reports the results obtained for the phase III clinical study in Japan for the addition of efficacy for “chronic pain” using the transdermal, long-acting cancer pain relief patch FENTOS® TAPE (development code HFT-290, hereinafter referred to as “the drug”).

The efficacy of the drug, administered once daily, was confirmed by a randomized, double-blind study. As a result, the efficacy of the drug was confirmed for patients with moderate to severe chronic pain.

Hisamitsu Pharmaceutical obtained approval for the drug in April 2010 with the efficacy for “pain relief in various cancers that accompany moderate to severe pain.” Also, Hisamitsu Pharmaceutical and Kyowa Hakko Kirin Co., Ltd., (head office: Chiyoda-ku, Tokyo, Japan; president: Nobuo Hanai) have jointly carried out product distribution and activities for the provision and collection of information (1 brand, 2 channels) since June 2010.

Hisamitsu Pharmaceutical aims for the application for the additional efficacy of the drug for “chronic pain” to be approved within this year.